US 12,168,695 B2
Bispecific antibody for cancer immunotherapy
Hatem Soliman, Tampa, FL (US)
Assigned to H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US)
Filed by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., Tampa, FL (US)
Filed on Jul. 1, 2022, as Appl. No. 17/810,447.
Application 17/810,447 is a continuation of application No. 16/058,398, filed on Aug. 8, 2018, granted, now 11,396,554.
Application 16/058,398 is a continuation of application No. 15/120,033, abandoned, previously published as PCT/US2015/061566, filed on Nov. 19, 2015.
Claims priority of provisional application 62/088,577, filed on Dec. 6, 2014.
Prior Publication US 2022/0380481 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/30 (2013.01) [C07K 16/2809 (2013.01); C07K 16/468 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01)] 6 Claims
 
1. A bispecific antibody, comprising
an anti-TAG72 single chain variable fragment (scFv) antibody that specifically binds human TAG72 linked to an anti-CD3 scFv that specifically binds human CD3 epsilon subunit,
wherein the anti-TAG72 scFv comprises a variable heavy (VH) domain and a variable light (VL) domain separated by a peptide linker,
wherein the VH domain comprises CDR1, CDR2 and CDR3 domains having the amino acid sequences of SEQ ID NOs: 12, 13 and 14, respectively, and
wherein the VL domain comprises CDR1, CDR2 and CDR3 domains having the amino acid sequences of SEQ ID NOs: 15, 16 and 17, respectively.